AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Epidemiological Study to Describe Non Small Cell Lung Cancer (NSCLC) Clinical Management Patterns in Central Eastern Europe and Russia (Lung-EPICLIN)
Completed
- Conditions
- Non Small Cell Lung Cancer
- First Posted Date
- 2010-02-17
- Last Posted Date
- 2015-05-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 840
- Registration Number
- NCT01069835
- Locations
- 🇷🇺
Research Site, Zhukovsky, Russian Federation
Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects
- First Posted Date
- 2010-02-15
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT01068756
- Locations
- 🇺🇸
Ppd Development, Austin, Texas, United States
Bioequivalence Study of 500 mg and 1000 mg Glucophage (Metformin) Tablets in Healthy Subjects
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2010-02-15
- Last Posted Date
- 2015-05-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT01068730
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-Administered
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2010-02-15
- Last Posted Date
- 2015-05-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT01068743
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)Drug: Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fed state)Drug: Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state)Drug: Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state)
- First Posted Date
- 2010-02-15
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 27
- Registration Number
- NCT01068717
- Locations
- 🇺🇸
Ppd Development, Lp, Austin, Texas, United States
A Study to Assess Safety, Tolerability and Pharmacokinetics of of AZD6553 in Healthy Volunteers and Patients With Chronic Obstructive Pulmonary Disease (COPD)
Phase 1
Terminated
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-02-12
- Last Posted Date
- 2010-09-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 109
- Registration Number
- NCT01068184
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD9742 After Multiple Doses Over 14 Days
- First Posted Date
- 2010-02-08
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT01064388
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients
- First Posted Date
- 2010-02-05
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 124
- Registration Number
- NCT01063517
- Locations
- 🇰🇷
Research Site, Taegu, Korea, Republic of
Study of the Clinical Management of Bipolar Disease
Completed
- Conditions
- Bipolar Disorders
- First Posted Date
- 2010-02-04
- Last Posted Date
- 2012-05-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2965
- Registration Number
- NCT01062607
- Locations
- 🇻🇪
Research Site, San Cristobal, Venezuela
Exenatide and Basal Insulins Use in the Real Setting: an Observational Study in Patients With Type 2 Diabetes
- First Posted Date
- 2010-02-02
- Last Posted Date
- 2015-04-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 888
- Registration Number
- NCT01060059
- Locations
- 🇮🇹
Research site, Varese, Italy